Should thrombolysis be recommended for diabetic stroke patients?

References

• The National Institute of Neurological Disorders and Stroke rt-PA Study Group. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med.333, 1581–1587 (1995).
   PubMed Web of Science ®Google Scholar
• The ATLANTIS, ECASS, and NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet363, 768–774 (2004).
   PubMed Web of Science ®Google Scholar
• Hacke W, Kaste M, Bluhmki E et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med.359, 1317–1329 (2008).
   PubMed Web of Science ®Google Scholar
• Lees KR, Bluhmki E, von Kummer R et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet375, 1695–1703 (2010).
   PubMed Web of Science ®Google Scholar
• Rubiera M, Alexandrov AV. Sonothrombolysis in the management of acute ischemic stroke. Am. J. Cardiovasc. Drugs.10, 5–10 (2010).
   PubMed Web of Science ®Google Scholar
• Ceriello A. Hyperglycaemia and the vessel wall: the pathophysiological aspects on the atherosclerotic burden in patients with diabetes. Eur. J. Cardiovasc. Prev. Rehabil.17, S15–S19 (2010).
   PubMedGoogle Scholar
• Rizvi AA. Cytokine biomarkers, endothelial inflammation, and atherosclerosis in the metabolic syndrome: emerging concepts. Am. J. Med. Sci.338, 310–318 (2009).
   PubMed Web of Science ®Google Scholar
• Giorda CB, Avogaro A, Maggini M et al.; The DAI Study Group. Incidence and risk factors for stroke in Type 2 diabetic patients: the DAI Study. Stroke38, 1154–1160 (2007).
   PubMed Web of Science ®Google Scholar
• Hill MD, Buchan AM; The CASES Investigators. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ172, 1307–1312 (2005).
   PubMed Web of Science ®Google Scholar
• Wahlgren N, Ahmed N, Davalos A et al.; SITS-MOST Investigators. Thrombolysis with alteplase for acute ischemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet369, 275–282 (2007).
   PubMed Web of Science ®Google Scholar
• Ahmed N, Davalos A, Eriksson N et al.; The SITS-investigators. Association of admission blood glucose and outcome in patients treated with intravenous thrombolysis results from the Safe Implementation of Treatments in Stroke International Stroke Thrombolysis Register (SITS-ISTR). Arch. Neurol.67, 1123–1130 (2010).
   PubMedGoogle Scholar
• Hacke W, Kaste M, Fieschi C et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA274, 1017–1025 (1995).
   PubMed Web of Science ®Google Scholar
• Hacke W, Kaste M, Fieschi C et al.; The Second European–Australasian Acute Stroke Study Investigators. Randomized double-blind placebo controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Lancet352, 1245–1251 (1998).
   PubMed Web of Science ®Google Scholar
• Wahlgren N, Ahmed N, Eriksson N et al.; The SITS-MOST Investigators. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials. Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST). Stroke39, 3316–3322 (2008).
   PubMed Web of Science ®Google Scholar
• Arnold M, Schroth G, Nedeltchev K et al. Intra-arterial thrombolysis in 100 patients with acute stroke due to middle cerebral artery occlusion. Stroke33, 1828–1833 (2002).
   PubMed Web of Science ®Google Scholar
• Zangerle A, Kiechl S, Spiegel M et al. Recanalization after thrombolysis in stroke patients predictors and prognostic implications. Neurology68, 39–44 (2007).
   PubMed Web of Science ®Google Scholar
• Demchuk AM, Tanne D, Hill MD, Kasner SE et al.; The Multicentre tPA Stroke Survey Group. Predictors of good outcome after intravenous tPA for acute ischemic stroke. Neurology57, 474–480 (2001).
   PubMed Web of Science ®Google Scholar
• Zairis MN, Lyras AG, Makrygiannis SS et al. Type 2 diabetes and intravenous thrombolysis outcome in the setting of ST elevation myocardial infarction. Diabetes Care27, 967–971 (2004).
   PubMed Web of Science ®Google Scholar
• Capes SE, Hunt D, Malmberg K et al. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke32, 2426–2432 (2001).
   PubMed Web of Science ®Google Scholar
• Poppe AY, Majumdar SR, Jeerakathil T et al. Admission hyperglycemia predicts a worse outcome in stroke patients treated with intravenous thrombolysis. Diabetes Care32, 617–622 (2009).
   PubMed Web of Science ®Google Scholar
• Weir CJ, Murray GD, Dyker AG, Lees KR. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long term follow up study. BMJ314, 1303–1306 (1997).
   PubMed Web of Science ®Google Scholar
• Ribo M, Molina C, Montaner J et al. Acute hyperglycemia state is associated with lower tPA-induced recanalization rates in stroke patients. Stroke36, 1705–1709 (2005).
   PubMed Web of Science ®Google Scholar
• Allport L, Baird T, Butcher K et al. Frequency and temporal profile of poststroke hyperglycemia using continuous glucose monitoring. Diabetes Care29, 1839–1844 (2006).
   PubMed Web of Science ®Google Scholar
• Yong M, Kaste M. Dynamic of hyperglycemia as a predictor of stroke outcome in the ECASS-II trial. Stroke39, 2749–2755 (2008).
   PubMed Web of Science ®Google Scholar
• The NINDS tPA Stroke Study Group. Generalized efficacy of t-PA for acute stroke: subgroup analysis of the NINDS t-PA stroke trial. Stroke28, 2119–2125 (1997).
   PubMed Web of Science ®Google Scholar
• Bluhmki E, Chamorro A, Davalos A et al. Stroke treatment with alteplase given 3.0–4.5 h after onset of acute ischemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol.8, 1074–1075 (2009).
   PubMed Web of Science ®Google Scholar
• Mishra NK, Lees KR, Davis SM, Kaste M. The VISTA Collaboration. Comparison of outcomes following thrombolytic therapy amongst patients with prior stroke and diabetes in the Virtual International Stroke Trials Archive. Diabetes Care33, 2531–2537 (2010).
   PubMed Web of Science ®Google Scholar
• Mishra NK. The VISTA and SITS Collaborators. Post thrombolysis outcomes amongst patients with prior stroke and diabetes: controlled comparison of SITS international registry (SITS-ISTR) versus Virtual International Stroke Trials Archive (VISTA). Cerebrovasc. Dis.29(Suppl. 2), 160 (2010).
   Google Scholar
• Demchuk AM, Morgenstern LB, Krieger DW et al. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke30, 34–39 (1999).
   PubMed Web of Science ®Google Scholar
• Jaillard A, Cornu C, Durieux A et al.; The MAST-E Group. Hemorrhagic transformation in acute ischemic stroke: the MAST-E study. Stroke30, 1326–1332 (1999).
   PubMed Web of Science ®Google Scholar
• Kerenyi L, Kardos L, Szasz J et al. Factors influencing hemorrhagic transformation in ischemic stroke: a clinicopathological comparison. Eur. J. Neurol.13, 1251–1255 (2006).
   PubMed Web of Science ®Google Scholar
• Celik Y, Utku U, Asil T, Balci K. Factors affecting hemorrhagic transformation in middle cerebral artery infarctions. J. Clin. Neurosci.11, 656–658 (2004).
   PubMed Web of Science ®Google Scholar